Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

C. Bain, Stephen; Mosenzon, Ofri; Arechavaleta, Rosario; Bogdański, Paweł; Çömlekçi, Abdurrahman; Consoli, Agostino; Deerochanawong, Chaicharn; Dungan, Kathleen; Cristina Faingold, María; E. Farkouh, Michael; Reis Franco, Denise; Gram, Jeppe; Guja, Cristian; Joshi, P; Malek, Rachid; Francisco Merino-Torres, Juan; A. Nauck, Michael; D. Pedersen, Sue; H.-H. Sheu, Wayne; Silver, Robert; J. Tack, Cees; Tandon, Nikhil; Kleist Jeppesen, Ole; Strange, Mette; S. Thomsen, Mette; Husain, Mansoor

doi:10.1111/dom.13553

Public

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Published in Diabetes Obesity and Metabolism • Oct 5, 2018

Authors:

Stephen C. Bain

Ofri Mosenzon

Rosario Arechavaleta

Abstract

AIMS: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon-like peptide-1 receptor agonist. MATERIALS AND METHODS: PIONEER 6 is a multinational, randomized, placebo-controlled, double-blind trial in patients with type 2 diabetes at high risk of CV ...

Subject

Medicine

Semaglutide

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!